Substituted 6-azabenzimidazole compounds

Patent metadata

Field	Value
Publication number	US-11897878-B2
Application number	US-202117522628-A
Country	US
Kind code	B2
Filing date	Nov 9, 2021
Priority date	Oct 31, 2018
Publication date	Feb 13, 2024
Grant date	Feb 13, 2024

Abstract

The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.

First claim

What is claimed is:

1. A compound of Formula:

or a pharmaceutically acceptable salt thereof.

2. A compound of Formula:

or a pharmaceutically acceptable salt thereof.

3. A compound of Formula:

or a pharmaceutically acceptable salt thereof.

4. A compound of Formula:

or a pharmaceutically acceptable salt thereof.

5. A compound of Formula:

or a pharmaceutically acceptable salt thereof.

6. A compound of Formula:

or a pharmaceutically acceptable salt thereof.

7. A compound of Formula:

or a pharmaceutically acceptable salt thereof.

8. A compound of Formula:

or a pharmaceutically acceptable salt thereof.

9. A compound of Formula:

or a pharmaceutically acceptable salt thereof.

10. A compound of Formula:

or a pharmaceutically acceptable salt thereof.

11. A compound of Formula:

or a pharmaceutically acceptable salt thereof.

12. A compound of Formula:

or a pharmaceutically acceptable salt thereof.

13. A compound of Formula:

or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition comprising the compound of claim 1 , or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

15. A pharmaceutical composition comprising the compound of claim 2 , or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

16. A pharmaceutical composition comprising the compound of claim 3 , or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

17. A pharmaceutical composition comprising the compound of claim 4 , or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

18. A pharmaceutical composition comprising the compound of claim 5 , or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

19. A pharmaceutical composition comprising the compound of claim 6 , or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

20. A pharmaceutical composition comprising the compound of claim 7 , or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

21. A pharmaceutical composition comprising the compound of claim 8 , or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

22. A pharmaceutical composition comprising the compound of claim 9 , or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

23. A pharmaceutical composition comprising the compound of claim 10 , or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

24. A pharmaceutical composition comprising the compound of claim 11 , or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

25. A pharmaceutical composition comprising the compound of claim 12 , or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

26. A pharmaceutical composition comprising the compound of claim 13 , or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

27. A method of inhibiting hematopoietic progenitor kinase 1 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 1 , or the pharmaceutically acceptable salt thereof.

28. A method of inhibiting hematopoietic progenitor kinase 1 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 2 , or the pharmaceutically acceptable salt thereof.

29. A method of inhibiting hematopoietic progenitor kinase 1 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 3 , or the pharmaceutically acceptable salt thereof.

30. A method of inhibiting hematopoietic progenitor kinase 1 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 4 , or the pharmaceutically acceptable salt thereof.

31. A method of inhibiting hematopoietic progenitor kinase 1 activity in a subject in need thereof, comprising administering to the subject the therapeutically effective amount of the compound of claim 5 , or a pharmaceutically acceptable salt thereof.

32. A method of inhibiting hematopoietic progenitor kinase 1 activity in a subject in need thereof, comprising administering to the subject the therapeutically effective amount of the compound of claim 6 , or a pharmaceutically acceptable salt thereof.

33. A method of inhibiting hematopoietic progenitor kinase 1 activity in a subject in need thereof, comprising administering to the subject the therapeutically effective amount of the compound of claim 7 , or a pharmaceutically acceptable salt thereof.

34. A method of inhibiting hematopoietic progenitor kinase 1 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 8 , or a the pharmaceutically acceptable salt thereof.

35. A method of inhibiting hematopoietic progenitor kinase 1 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 9 , or the pharmaceutically acceptable salt thereof.

36. A method of inhibiting hematopoietic progenitor kinase 1 activity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 10 , or the pharmaceutically acceptable salt thereof.

37

Assignees

• Gilead Sciences Inc

Inventors

• Balan Gayatri
• Bartlett Mark J
• Chandrasekhar Jayaraman
• Codelli Julian A
• Conway John H
• Cosman Jennifer L
• Kalla Rao V
• Kasun Zachary A
• Kim Musong
• Lee Seung H
• Lo Jennifer R
• Loyer-Drew Jennifer A
• Mitchell Scott A
• Perry Thao D
• Phillips Gary B
• Salvo Patrick J
• Swaminathan Sundaramoorthi
• Van Veldhuizen Joshua J
• Yeung Suet C
• Zablocki Jeff

Classifications

• A61P31/20

  for DNA viruses · CPC title

• A61P31/18

  for HIV · CPC title

• C07D471/04 Primary

  Ortho-condensed systems · CPC title

• C07D519/00

  Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title